NCPC-626

NCPC-626 is a novel, potent pan-peroxisome proliferator-activated receptor (PPAR) agonist discovered from natural fungal metabolites. It exhibits balanced activation across the three PPAR isoforms: alpha (PPARα), beta/delta (PPARβ/δ), and gamma (PPARγ). Preclinical studies indicate that NCPC-626 effectively alleviates metabolic dysfunction-associated steatohepatitis (MASH) by inhibiting hepatic lipid accumulation, reducing inflammation, and preventing fibrosis. Additionally, the compound has demonstrated the ability to improve glucose tolerance, reduce body weight, and lower liver triglyceride levels in diabetic and obese mouse models (db/db mice). With its unique chemical scaffold, NCPC-626 is being investigated as a potential therapeutic agent for MASH and related metabolic disorders.